On June 21, 2022 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research (Press release, Anixa Biosciences, JUN 21, 2022, View Source [SID1234616136]). The article is titled, "Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas." This paper authored by Suparna Mazumder, Ph.D., Valerie Swank, MS, Nina Dvorina, MD, Justin M. Johnson, Ph.D. and Vincent K. Tuohy, Ph.D. of Cleveland Clinic, discusses pre-clinical studies of a preventative ovarian cancer technology that has been licensed to Anixa.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.
The journal article highlights study data demonstrating formulation of the AMHR2-ED vaccine with AddaVax adjuvant induced high serum titers of immunoglobulin G and significant inhibition and destruction of epithelial ovarian cancer with significantly enhanced overall survival of animals in both prevention and therapeutic protocols.
Anixa’s CEO, Amit Kumar, Ph.D., stated, "We are pleased by the publication of this scientific paper authored by our partners at Cleveland Clinic. This unique technology has the potential to be the first vaccine to prevent ovarian cancer, which remains one of the most aggressive and difficult-to-treat cancers." Dr. Kumar added, "Preclinical work to advance the vaccine is ongoing with support from the PREVENT Program at the National Cancer Institute (NCI), which supports preclinical innovative interventions and biomarkers for cancer prevention and interception."
The Clinical and Experimental Vaccine Research article is available to view at the following link: View Source